Phase I / II study for appropriate dose of Erlotinib in patients with lung adenocarcinoma having the sensitive mutation to epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitor (TKI).

Trial Profile

Phase I / II study for appropriate dose of Erlotinib in patients with lung adenocarcinoma having the sensitive mutation to epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitor (TKI).

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 May 2016

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Nov 2013 Status changed from suspended to recruiting as reported by University Hospital Medical Information Network - Japan.
    • 25 Aug 2013 Status changed from recruiting to suspended as reported by University Hospital Medical Information Network - Japan.
    • 25 Aug 2011 Status changed from suspended to recruiting University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top